PhosPrint P.C. was founded in 2019 as a spin-off of the Institute of Communication and Computer Systems of the National Technical University of Athens (ICCS/NTUA) and is established at the Lefkippos Technology Park.
Our product is a semi-autonomous, laser bioprinting system dedicated to the high-resolution and high-precision printing of cells, biomolecules and drugs. Our laser printer is unique as it is the first compact, desk top laser bioprinter at prototype TRL level 6 (Technology Readiness Level). Two upside opportunities are the production of 3D printing products and licensing agreements of the technology for bioreagents and cells.
We have a priority PCT in the filing of related applications [“Dual beam laser transfer”, Ioanna Zergioti, Symeon Papazoglou, PCT/EP2017/084740, 28/12/2017], and the freedom to operate in the Laser-Induced Bioprinting (LIB) process with our unique Dual Laser Induced Bioprinting (D-LIB). Laser bioprinting is currently under development for the creation of tissues and organs suitable for regeneration and drug screening, eventually aiming to cure untreatable medical conditions, impacting the lives of millions while decreasing health care costs. Out of the bioprinting methods used, laser bioprinting achieves the highest degree of precision and resolution of printed structures offering a significant advantage for the printing of biomaterials. Our targeted market is the Laser Segment of the Global Healthcare 3D Printing market, focusing on the subsegment for surgery units with applications in tissue regeneration. The Laser Segment is estimated at 25% of the total Healthcare 3D Printing market and valued at USD 239 Mn in 2017; it is expected to reach USD 780 Mn by 2025.
